Zhang Xu | Thoracic Surgery | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Zhang Xu

Title: Associate Professor

Email: zhangxu@sysucc.org.cn

Phone:

Profile

Dr. Zhang Xu is the associate professor of surgery . He has been working in the Department of Thoracic Surgery, Cancer Center, Sun Yet –Sen University for 17 years after graduated from Sun Yet-Sen University of Medical Science in July 1997. He is very familiar with the diagnosis and treatment of thoracic tumor including carcinoma of lung, esophagus, breast cancer and mediastium. The responsibilities include :esophagoscopy, tracheoscopy, endscopic ultrasonography (EUS),thoracoscopy, mediastinoscopy,lobectomy, pneumoectomy, mediastinal lymph node dissection(opening or VATS),Lobar bronchoplasty,e sophagectomy with intrathoracic or cervical anastomosis(opening or VATS),mediastinal tumor resection,tumor of chest wall resection and reconstruction,radical and modified mastectomy,multidisciplinary management of cancer of lung and esophagus. Dr. Zhang has published more than 30 research papers.

Interests

1. Detecting the related genes in esophageal carcinoma.

2. Multidisciplinary management of cancer of lung and esophagus.3. The pattern of lymph node metastasis in esophageal carcinoma

Education

1986 - 1992 First High School of Puning, Gaungdong Province.

1992 - 1997 Sun Yet-Sen University of Medical Science ( now Sun Yet-Sen University ), Bachelor of Clinical Medicine

2001 – 2004 Sun Yet-Sen University, Master of Oncology

2005 – 2008 Sun Yet-Sen University, PhD of Oncology

Publications

1. Zhang X, LinP, ZhuZH, LongH, WenJ, YangH, ZhangX, WangDF, FuJH, FangY, RongTH. Expressionprofiles of early esophageal squamous cell carcinoma by cDNA microarray[J]. Cancer Genet Cytogenet . 2009, 194(1):23-29.

2. Zhang X, ChenSB, ChenJX, WenJ, YangH, XieMR, ZhangY, HuYZ, LinP. CK19 mRNA expression in the bone marrow ofpatients with esophageal squamous cell carcinoma and its clinical significance[J]. Dis Esophagus. 2010,23(1):437-443

3. Gao YH, Zhang X, An X, Cai MY, Zeng ZF, Chen G, Kong LH, Lin JZ, Wan DS, Pan ZZ, Ding PR. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locallyadvanced rectal cancer[J]. Strahlenther Onkol. 2014, 190(2): 158-164.(Co first author)

4. Zhang X, ZhuZH, LinP, YangH, FuJH, ZhangLJ, LongH, WenJ, HuangXP, FangY, RongTH. Analyzing the profile of chromosomal imbalances in esophageal atypical hyperplasia and early stage esophageal squamous cell carcinoma by 250K Snp Array[J]. ZhonghuaYi Xue Za Zhi. 2008,88(37):2636-2641.

5. Zhang X, Rong TH, Wu QL, Fu JH, Long H,Zhang LJ, Ma GW, Su XD, Li XD, Wang DF, Hu Y, Yang H. Differential diagnosis andtreatment of esophageal stromal tumors and smooth muscle tumors

6. Zhang X, Hung XP, Ma GW. Cyclin D1 expression in esophageal cancer and its clinical significance[J]. Journalof Sun Yat-Sen University. 2006,27(6):657-660.

7. Zhang X, RongTH, ZhangY, LongH, FuJH, LingP, ZhangLJ, YangMT, ZengCG, MaGW, SuXD, LiXD, WangJY, WenZS, ZhaoJM. Expression and significance of C-kit and platelet-derivedgrowth factor receptor-beta (PDGFRβ) in esophageal cancer[J]. Ai Zheng. 2006, 25(1):92-95.

8. Zhang X, Huang XP, Ma GW. Investigation of the key gene in 8q24 amplifications in esophageal cancer[J]. Chin J Oncol. 2007, 34(13):724－727.

9. Zhang X, Rong TH, Fu JH. Diagnosis and treatment of esophagealleiomyosarcomas[J]. Chinese Journal of Clinical Oncology andRehabilitation. 2005,12(5):452-454.

10. ZhangX, Huang XP, FuJH, LingP, ZhangLJ, YangMT, ZengCG, MaGW.Flake endonuclease expression in esophageal squamous cell carcinoma and itsclinical significance[J].Guoji Zhong Liu Xue Za Zhi. 2007,34(11):876-878.

11. Liang YJ, Zhang X, Dai CL, Zhang JY, Yan YY, Zeng MS, Chen LM, Fu LW.Bullatacintriggered ABCB1-overexpressing cell apoptosis via the mitochondrial-dependentpathway[J]. JBiomed Biotechnol. 2009:867123.

12. ZhouWJ, Zhang X, ChengC, WangF, WangXK, LiangYJ, ToKK, ZhouW, HuangHB, FuLW.Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein[J]. Br J Pharmacol. 2012,166(5):1669-1683.

13. XieMR, Zhang X, LinP, LinYB, RongTH, ZhangLJ, WenZS, LiXD.Short and long-term outcomes of neoadjuvant chemotherapy for locally advancedesophageal carcinoma [J]. ZhonghuaYi Xue Za Zhi. 2009,89(41):2906-2909.

14. HuangXP, Zhang X, SuXD, MaGW, ZhaoJM, RongTH.Expression and significance of MCM4 in esophageal cancer [J]. Ai Zheng. 2007, 26(1):96-99.

15. Xie MR, Zhang X, Lin P, Chen JX, Ling YB, Fu JH, Rong TH, Zeng CG, Huang ZF.Safety and long-term outcome of sleeve lobectomy for non-small cell lungcancer[J]. Ai Zheng. 2009,28(8):868-871.

16. Yan YY, Zheng LS, Zhang X, Chen LK, Singh S, Wang F, Zhang JY, Liang YJ, Dai CL, Gu LQ, Zeng MS, T Talele T, Chen ZS, Fu LW. Blockade of Her2/neubinding to Hsp90 by emodin azide methyl anthraquinone derivative inducesproteasomal degradation of Her2/neu[J].Mol Pharm. 2011,8(5):1687-1697.

17. LaiRC, WangXD, Zhang X, LinWQ, RongTH. Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity inrabbits[J]. Med Oncol. 2012,29(3):2303-2308..

18. YangHX, LingL, Zhang X, LinP, RongTH, FuJH. Outcome of elderly patients withoesophageal squamous cell carcinoma after surgery[J]. Br J Surg, 2010, 97(6): 862–867.

19. SuX, MaG, Zhang X, LongH, RongTH. Surgical approach and outcomes for treatment ofpulmonary metastases[J]. AnnThorac Med, 2013,8(3):160-164.

20. WangXW, WangXK, Zhang X, LiangYJ, ShiZ, ChenLM, FuLW. FG020326 sensitizedmultidrug resistant cancer cells to docetaxel-mediated apoptosis viaenhancement of caspases activation[J]. Molecules. 2012,17(5):5442-5458.

21. Liao H, Rao H, ZhangX, Lin Y, Jie M, Fu J, Long H, Rong T, Lin P.Retrospective study ofclinicopathological characteristics in bronchopulmonary carcinoid[J]. Zhongguo Fei Ai Za Zhi, 2010 ,13(6):591-597.

22. ChenLM, LiYF, Zhang X, YanSL, LiangYJ, FuLW.Reversal of multidrug resistance of tumor cells by FG020327 and itsmechanism[J]. Ai Zheng. 2005,24(2):189-193.

23. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF, Fu JH. Establishment andbiological analysis of the EC109/CDDP multidrug-resistant esophageal squamouscell carcinoma cell line [J]. OncolRep. 2009, 22(1):65-71.

24. Dai CL, Liang YJ, Chen LM, Zhang X, Deng WJ, Su XD, Shi Z, Wu CP, Ashby CR Jr, Akiyama S, Ambudkar SV, Chen ZS, Fu LW.Sensitizationof ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 viabinding to ABCB1 and inhibiting its function[J]. BiochemPharmacol. 2009,78 (4):355-364.

25. Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol. 2012,83(5):586-597.

26. DaiCL, XiongHY, TangLF, Zhang X, LiangYJ, ZengMS, ChenLM, WangXH, FuLW.Tetrandrine achieved plasma concentrations capable of reversing MDR in vitroand had no apparent effect on doxorubicin pharmacokinetics in mice[J]. Cancer Chemother Pharmacol. 2007 , 60(5):741-750.

27. Li-sheng Zheng, Fang Wang , Yu-hong Li, Xu Zhang, Li-ming Chen, Yong-ju Liang, Chun-ling Dai,Yan-yan Yan,Li-yang Tao, Yan-jun Mi, An-kui Yang, Kenneth Kin Wah To, Li-wu Fu. Vandetanib(Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance byInhibition of Their Transport Function[J]. PLoS One. 2009, 4(4):e5172.

28. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Li Y, Zhang CY, Luo KJ, Zang X, Li YF, Guan XY, FuJH. Comparative proteomic analysis ofthe esophageal squamous carcinoma cell line EC109 and its multi-drug resistantsubline EC109/CDDP [J]. Int JOncol .2010, 36(1): 265-274.

29. Lai RC, Long YH, Li QL, ZhangX, Rong TH. Oxidative stress markers may not be early markers ofdoxorubicin-induced cardiotoxicity in rabbits[J].Exp Ther Med 2011, 2 (5): 947-950

30. ZhaoXQ, XieJD, ChenXG, SimHM, Zhang X, LiangYJ, SinghS, TaleleTT, SunY, AmbudkarSV, ChenZS, FuLW. Neratinib reversesATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, invivo, and ex vivo[J].Mol Pharmacol. 2012 ,82(1):47-58.

31. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, ZhangX, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH.Threeimmunomarker support vector machines-based prognostic classifiers for stage IBnon-small-cell lung cancer [J]. JClin Oncol. 2009, 27(7):1091-1099.

32. SituD, LongH, LinP, ZhuZ, WangJ, Zhang X, XieZ, RongT. Expression andprognostic relevance of CD44v6 in stage I non-small cell lung carcinoma [J]. J Cancer Res Clin Oncol. 2010,136 (8):1213-1219.

Last Updated on: August 2014 by International Office, Sun Yat-sen University Cancer Center

Our Experts